Bristol-Myers Squibb plans to construct a new large-scale biologics manufacturing facility in Dublin, Ireland to produce multiple therapies for the company’s biologics portfolio. Once completed, the new facility will significantly increase BMS’s biologics manufacturing capacity and play a central role in its global manufacturing network. The company’s portfolio of approved and investigational biologics covers multiple therapeutic areas including oncology, virology and immunoscience.   The 30,000...